Does Testosterone Cause Prostate Cancer? TRT Facts

TL;DR

Raising testosterone from a hypogonadal to a normal (eugonadal) level does not increase prostate cancer risk, according to the TRAVERSE trial. Only 23 prostate cancers appeared among 5,300+ men, and men with low PSA stayed low-risk. TRT is considered safe even in men with low-grade prostate cancer under surveillance, where maintaining total health is the goal.

Transcript

are there any scenarios where in an cancer-free patient you would advise against trt I would say there's I can't think of any scenarios where I really advise against uh trt for somebody who is symptomatic and and has um you know there's so many other you know potential negative outcomes for a patient who has low tea besides the possible development... Read More

Key Insights

• The TRAVERSE trial found no increase in prostate cancers among hypogonadal men on testosterone replacement versus placebo, with only about 23 cancers detected across a cohort of more than 5,300 men, an incredibly low overall incidence.
• PSA remains usable during testosterone therapy. Most men in TRAVERSE saw their PSA change less than half a point, and those whose PSA rose were the ones later at higher risk of being identified as harboring prostate cancer.
• TRAVERSE enrolled a low-risk group: men in their 60s on average, hypogonadal, with a mean PSA around 0.9, then raised testosterone only a small amount (140 ng/ml) to barely eugonadal levels, limiting how much risk could emerge.
• The saturation theory holds that once androgen receptors in an organ are fully bound, additional testosterone or DHT produces limited extra effect, so supplementing beyond that threshold yields little augmented output from the receptor.
• Androgen receptor saturation levels vary by organ. Prostate saturation is estimated at serum testosterone around 2 to 250 ng/ml, quite low, while muscle requires much higher levels to drive anabolic growth and mass.
• Benign prostatic cells carry higher densities of androgen receptor than cancerous cells, making them more sensitive to testosterone, which is why supplementation more often worsens BPH or urinary symptoms than it progresses cancer.
• For men with low-grade prostate cancer on active surveillance, testosterone replacement can be maintained. The goal of surveillance is optimizing total health, keeping the patient in a eugonadal state for cardiovascular, bone, muscle, and cognitive benefits.
• The TRAVERSE incidence curves diverged slightly but never reached statistical significance, likely because the sample and duration were too small. A 10-year or 10-times-larger study might reveal a difference, though that remains unknown.

Questions & Answers

Q: Does testosterone replacement therapy increase prostate cancer risk?

Based on the TRAVERSE trial, no. In a large cohort of more than 5,300 hypogonadal men, a pre-specified secondary analysis found no more prostate cancers diagnosed in men on testosterone replacement than on placebo. The total number of cancers detected was very low, about 23, giving a low overall incidence. Bringing a man from a hypogonadal to a barely eugonadal state did not measurably raise his risk of being diagnosed with prostate cancer.

Q: What did the TRAVERSE trial actually study regarding prostate cancer?

TRAVERSE enrolled hypogonadal men with symptoms and raised their testosterone toward eugonadal levels, though the bump was small at 140 ng/ml and dropout exceeded 60 percent at five years. It tested whether exogenous testosterone would fuel a pre-existing prostate cancer or induce a new cancer in a low-testosterone man. The mean PSA was around 0.9, and men averaged in their 60s, making this a low-risk group.

Q: Can PSA still be used to monitor men on testosterone therapy?

Yes. TRAVERSE showed PSA can be used in generally similar fashion when supplementing a man with exogenous testosterone. Most men saw their PSA change less than half a point over the trial. For the minority whose PSA did rise, those were the men subsequently at higher risk of being identified as harboring a prostate cancer, so tracking PSA changes remains a meaningful screening approach during treatment.

Q: What is the androgen receptor saturation theory?

The saturation theory states that once androgens reach a certain level within an end organ, such as prostate, muscle, or hair follicle, the androgen receptor becomes fully saturated. Beyond that point, additional testosterone or DHT produces limited extra effect on receptor engagement with DNA. Giving more androgen yields diminishing returns because the receptors are already occupied. This concept is common across receptor superfamilies, not unique to the androgen receptor.

Q: Why does testosterone affect the prostate and muscle differently?

Saturation thresholds vary by organ. Within the prostate, androgen receptor saturation is estimated at serum testosterone levels around 2 to 250 ng/ml, which is fairly low, so the prostate saturates early. Muscle requires much higher levels to achieve anabolic effects that promote growth and mass. Hair follicles resemble the prostate, having high densities of 5-alpha reductase to convert testosterone to DHT, so the effect of testosterone differs across end organs.

Q: Why does testosterone worsen BPH but not necessarily fuel prostate cancer?

Benign prostatic cells carry much higher densities of androgen receptor than cancerous cells, making them more sensitive to testosterone supplementation. Studies over the past two to three decades in urology show that supplementing testosterone in eugonadal men more often than not worsens BPH or urinary symptoms. This reflects the greater sensitivity of benign cells to exogenous testosterone rather than development or progression of an actual prostate cancer.

Q: Should men with prostate cancer avoid testosterone replacement therapy?

It depends on cancer aggressiveness. For a man with low-grade prostate cancer on active surveillance, the expert maintains testosterone replacement, because the goal of surveillance is to optimize total health. Keeping the patient in a eugonadal state preserves cardiovascular health, bone health, muscle mass, and cognitive function. If a man on replacement is diagnosed with low-grade cancer, the expert continues the therapy rather than stopping it.

Q: Are there scenarios where TRT should be avoided in a cancer-free patient?

The urologist could not think of any scenario where he would truly advise against TRT for a symptomatic hypogonadal patient. Low testosterone carries many potential negative outcomes beyond prostate cancer concerns. For a hypogonadal man, the priority is maintaining cardiovascular health, bone health, muscle mass, and cognitive function, so the aim is to bring him into a eugonadal state rather than withhold treatment.

Summary & Key Takeaways

• The TRAVERSE trial asked whether exogenous testosterone raises prostate cancer risk in hypogonadal men. A pre-specified secondary analysis found no more prostate cancers on testosterone than placebo, with only about 23 cancers among 5,300-plus men, a reassuring result for a low-risk cohort with mean PSA near 0.9.

• Androgens, testosterone and the higher-affinity DHT, drive prostate growth and differentiation, but benign cells hold more androgen receptors than cancer cells, so supplementation more often worsens BPH symptoms than progresses cancer. The saturation theory explains why extra androgens above a threshold add little effect within an organ.

• Saturation thresholds differ by organ: prostate saturates at low serum testosterone (roughly 2 to 250 ng/ml) while muscle needs far higher levels for anabolic effect. For patients with low-grade prostate cancer on surveillance, testosterone replacement is maintained to preserve cardiovascular, bone, muscle, and cognitive health.